Antigen–Antibody Complexes

Antigen–antibody complexes are formed when the body's immune system raises antibodies against antigenic determinants of host or foreign substances that recognize and bind to the unwanted molecules. Normally, the immune complexes that are formed are cleared by the cellular immune system, but when an excess of antibody or antigen is present, the immune complexes are either detected in tissues or involved in the pathogenesis of tissue lesions in a variety of diseases.

Keywords: complement; antigens; antibodies; immune complexes diseases

Figure 1. Types of antibody–antigen complexes formed. (a) Antibodies of the class IgM, IgA, IgG or IgE can bind to IgG and form small soluble or larger insoluble complexes that are deposited in various tissues of the body. IgM rheumatoid factors are the most frequently formed and react with modified Fc regions of IgG. (b) Posttranslation modification of host proteins during stress can potentially lead to over stimulation of the immune response resulting in proteolytic fragments of self antigen eliciting an autoimmune response. (c) Peptides can be generated from host antisense DNA or peptides from microbes that arose from DNA sequences homologous to antisense DNA. The complementary peptides initiate the production of antibodies, which in turn trigger release of autoantibodies against self antigens. (d) The majority of circulating antibodies recognize and bind to either soluble ‘nonself’ or foreign antigens or attach to epitopes on the surface of microorganisms, enhancing complement fixation and lysis of microorganisms, followed by clearance by phagocytes.
Figure 2. Failure of maintaining self-tolerance to antigens due to posttranslational modification. (a) During the process of apoptosis, host proteins cluster in specific subcellular compartments. Ribosomal antigens and endoplasmic reticulum proteins localize in small blebs, while nuclear autoantigens cluster in apoptotic bodies. These are then recognized by various systemic proteins such as C1q, C-reactive protein and serum amyloid P and removed in a noninflammatory way by the phagocytic system. (b) However, if these clearance mechanisms are defective then the apoptotic bodies and blebs eventually release their intracellular components, which can be proteolytically cleaved by a number of enzymes or modified by oxidative stress conditions. (c) Modification of proteins by proteolytic enzymes can expose cleavage sites in proteins or generate distinct amino acid fragments that are targets for antibody in various autoimmune diseases. These modifications include proteolytic cleavage by caspases or granzyme B, transglutamination, (de)phosphorylation and also citrullination. Nonenzymatic modifications of proteins can arise from direct exposure to reactive oxygen, chlorine, sulfur or nitrogen species. These proteins can then be engulfed by professional antigen-presenting cells and then present modified host peptides to helper T cells, which in turn can trigger effector B cells to generate antibodies against modified self peptides.
close
 References
    Botto M, Dell’Agnola C, Bygrave AE et al. (1998) Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nature Genetics 19: 3–4.
    Casciola-Rosen LA, Anhalt G and Rosen A (1994) Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. Journal of Experimental Medicine 179: 1317–1330.
    book Davies KA (2000) "Immune complexes and autoimmunity". In: Lahita RG, Chiorazzi N and Reeves WH (eds) Textbook of the Autoimmune Diseases, pp. 137–151. Philadelphia: Lippincott, Williams and Wilkins
    Davies KA, Robson MG, Peters AM et al. (2002) Defective Fc-dependent processing of immune complexes in patients with systemic lupus erythematosus. Arthritis and Rheumatism 46: 1028–1038.
    Edwards JCW and Cambridge G (1998) Rheumatoid arthritis: The predictable effect of small immune complexes in which antibody is also antigen. British Journal of Rheumatology 37: 126–130.
    Kim SJ, Gershov D, Ma X, Brot N and Elkon KB (2002) I-PLA(2) activation during apoptosis promotes the exposure of membrane lysophosphatidylcholine leading to binding by natural immunoglobulin M antibodies and complement activation. Journal of Experimental Medicine 196: 655–665.
    Pendergraft WF III, Preston GA, Shah RR et al. (2004) Autoimmunity is triggered by cPR-3(105-201), a protein complementary to human autoantigen proteinase-3. Nature Medicine 10: 72–79.
    Sullivan KE, Jawad AF, Piliero LM et al. (2003) Analysis of polymorphisms affecting immune complex handling in systemic lupus erythematosus. Rheumatology 42: 446–452.
    Waaler E (1940) On the occurrence of a factor in human serum activating the specific agglutination of sheep red blood corpuscles. Acta Pathologica et Microbiologica Scandinavia 17: 172–188.
 Further Reading
    Davies KA (1997) Complement, immune complexes and systemic lupus erythematosus. British Journal of Rheumatology 35: 3–23.
    book Lawley TJ (1995) "Immune complexes". In: Frank MM, Austin K, Claman HN and Unanue ER (eds) Smaster's Immunologic Diseases, 5th ed., pp. 321–330. Boston: Little Brown
    book Maddison PJ and Huey P (2004) "Serological profile". In: Isenberg DA, Maddison PJ, Woo P, Glass D and Breedveld FC (eds) Oxford Textbook of Rheumatology, 3rd edn, pp. 491–499. Oxford: Oxford University Press
    book Rosen A and Cascioloa-Rosen L (2003) "Autoantigens as substrates for apoptotic proteases: implications for the pathogenesis of systemic autoimmune disease". In: Kalden JR and Herrmann M (eds) Apoptosis and Autoimmunity from Mechanisms to Treatments, 1st ed., pp. 245–261. Weinheim: Wiley
Contact Editor close
Submit a note to the editor about this article by filling in the form below.

* Required Field

How to Cite close
Eggleton, Paul(Jan 2006) Antigen–Antibody Complexes. In: eLS. John Wiley & Sons Ltd, Chichester. http://www.els.net [doi: 10.1038/npg.els.0001118]